NNVC
NanoViricides, Inc.
Biotechnology
Market Cap$31M
5Y Perf.-81.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
NNVC vs GILD
Revenue, margins, valuation, and 5-year total return — side by side.
GILD
Gilead Sciences, Inc.
Drug Manufacturers - General
Market Cap$166.40B
5Y Perf.+72.2%
NNVC vs GILD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | NNVC | GILD |
|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - General |
| Market Cap | $31M | $166.40B |
| Revenue (TTM) | $0.00 | $29.73B |
| Net Income (TTM) | $-2.22T | $9.22B |
| Gross Margin | — | 63.0% |
| Operating Margin | — | 38.2% |
| Forward P/E | — | 15.7x |
| Total Debt | $0.00 | $24.59B |
| Cash & Equiv. | $2M | $7.56B |
NNVC vs GILD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NNVC
GILD
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| NanoViricides, Inc. (NNVC) | 100 | 18.9 | -81.1% |
| Gilead Sciences, In… (GILD) | 100 | 172.2 | +72.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NNVC vs GILD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: GILD leads in 6 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
NNVC
NanoViricides, Inc.
The Specific-Use Pick
In this particular matchup, NNVC is outpaced on most metrics by others in the set.
Best for: healthcare exposure
GILD
Gilead Sciences, Inc.
The Income Pick
GILD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 11 yrs, beta 0.66, yield 2.4%
- Rev growth 2.4%, EPS growth 16.8%, 3Y rev CAGR 2.6%
- 87.8% 10Y total return vs NNVC's -95.5%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | GILD | 2.4% revenue growth vs NNVC's -258K% |
| Quality / Margins | GILD | 31.0% margin vs NNVC's 1.4% |
| Stability / Safety | GILD | Beta 0.66 vs NNVC's 1.34 |
| Dividends | GILD | 2.4% yield; 11-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | GILD | +38.8% vs NNVC's +14.5% |
| Efficiency (ROA) | GILD | 16.1% ROA vs NNVC's -18.1%, ROIC 23.4% vs -114.0% |
NNVC vs GILD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
NNVC vs GILD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLGILDLAGGINGNNVC
NNVCNanoViricides, Inc.
1leads
GILDGilead Sciences, Inc.
5leads
6 Total Categories
CATEGORYLEADERvs NNVCMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
GILD1/1
Valuation MetricsMultiples, price ratios, and targets
NNVC2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
GILD5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
GILD5/6
Risk & VolatilityBeta, volatility, and downside exposure
GILD2/2
Analyst OutlookRatings, price targets, and dividends
GILD1/1
Income & Cash Flow (Last 12 Months)
GILD leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
GILD and NNVC operate at a comparable scale, with $29.7B and $0 in trailing revenue.
| Metric | NNVCNanoViricides, In… | GILDGilead Sciences, … |
|---|---|---|
| RevenueTrailing 12 months | $0 | $29.7B |
| EBITDAEarnings before interest/tax | -$8M | $12.1B |
| Net IncomeAfter-tax profit | -$2.22T | $9.2B |
| Free Cash FlowCash after capex | -$3.73T | $10.3B |
| Gross MarginGross profit ÷ Revenue | — | +63.0% |
| Operating MarginEBIT ÷ Revenue | — | +38.2% |
| Net MarginNet income ÷ Revenue | — | +31.0% |
| FCF MarginFCF ÷ Revenue | — | +34.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +4.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +21.4% | +54.8% |
GILD leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
NNVC leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | NNVCNanoViricides, In… | GILDGilead Sciences, … |
|---|---|---|
| Market CapShares × price | $31M | $166.4B |
| Enterprise ValueMkt cap + debt − cash | $29M | $183.4B |
| Trailing P/EPrice ÷ TTM EPS | -2.25x | 19.77x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 15.69x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.15x |
| EV / EBITDAEnterprise value multiple | — | 16.95x |
| Price / SalesMarket cap ÷ Revenue | — | 5.65x |
| Price / BookPrice ÷ Book value/share | 2.86x | 7.44x |
| Price / FCFMarket cap ÷ FCF | — | 17.60x |
NNVC leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
GILD leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
GILD delivers a 42.3% return on equity — every $100 of shareholder capital generates $42 in annual profit, vs $-20 for NNVC. On the Piotroski fundamental quality scale (0–9), GILD scores 9/9 vs NNVC's 1/9, reflecting strong financial health.
| Metric | NNVCNanoViricides, In… | GILDGilead Sciences, … |
|---|---|---|
| ROE (TTM)Return on equity | -20.1% | +42.3% |
| ROA (TTM)Return on assets | -18.1% | +16.1% |
| ROICReturn on invested capital | -114.0% | +23.4% |
| ROCEReturn on capital employed | -101.1% | +25.1% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 9 |
| Debt / EquityFinancial leverage | — | 1.09x |
| Net DebtTotal debt minus cash | -$2M | $17.0B |
| Cash & Equiv.Liquid assets | $2M | $7.6B |
| Total DebtShort + long-term debt | $0 | $24.6B |
| Interest CoverageEBIT ÷ Interest expense | — | 8.87x |
GILD leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
GILD leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GILD five years ago would be worth $22,418 today (with dividends reinvested), compared to $3,912 for NNVC. Over the past 12 months, GILD leads with a +38.8% total return vs NNVC's +14.5%. The 3-year compound annual growth rate (CAGR) favors GILD at 22.2% vs NNVC's 3.5% — a key indicator of consistent wealth creation.
| Metric | NNVCNanoViricides, In… | GILDGilead Sciences, … |
|---|---|---|
| YTD ReturnYear-to-date | +17.4% | +10.9% |
| 1-Year ReturnPast 12 months | +14.5% | +38.8% |
| 3-Year ReturnCumulative with dividends | +10.9% | +82.4% |
| 5-Year ReturnCumulative with dividends | -60.9% | +124.2% |
| 10-Year ReturnCumulative with dividends | -95.5% | +87.8% |
| CAGR (3Y)Annualised 3-year return | +3.5% | +22.2% |
GILD leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
GILD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
GILD is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than NNVC's 1.34 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GILD currently trades 85.2% from its 52-week high vs NNVC's 63.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NNVCNanoViricides, In… | GILDGilead Sciences, … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.34x | 0.66x |
| 52-Week HighHighest price in past year | $2.23 | $157.29 |
| 52-Week LowLowest price in past year | $0.85 | $95.30 |
| % of 52W HighCurrent price vs 52-week peak | +63.7% | +85.2% |
| RSI (14)Momentum oscillator 0–100 | 67.0 | 52.6 |
| Avg Volume (50D)Average daily shares traded | 249K | 5.8M |
GILD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
GILD leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
GILD is the only dividend payer here at 2.38% yield — a key consideration for income-focused portfolios.
| Metric | NNVCNanoViricides, In… | GILDGilead Sciences, … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $161.88 |
| # AnalystsCovering analysts | — | 58 |
| Dividend YieldAnnual dividend ÷ price | — | +2.4% |
| Dividend StreakConsecutive years of raises | 2 | 11 |
| Dividend / ShareAnnual DPS | — | $3.19 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.2% |
GILD leads this category, winning 1 of 1 comparable metric.
Key Takeaway
GILD leads in 5 of 6 categories (Income & Cash Flow, Profitability & Efficiency). NNVC leads in 1 (Valuation Metrics).
Best OverallGilead Sciences, Inc. (GILD)Leads 5 of 6 categories
Loading custom metrics...
NNVC vs GILD: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is NNVC or GILD a better buy right now?
Gilead Sciences, Inc.
(GILD) offers the better valuation at 19. 8x trailing P/E (15. 7x forward), making it the more compelling value choice. Analysts rate Gilead Sciences, Inc. (GILD) a "Buy" — based on 58 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — NNVC or GILD?
Over the past 5 years, Gilead Sciences, Inc.
(GILD) delivered a total return of +124. 2%, compared to -60. 9% for NanoViricides, Inc. (NNVC). Over 10 years, the gap is even starker: GILD returned +87. 8% versus NNVC's -95. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — NNVC or GILD?
By beta (market sensitivity over 5 years), Gilead Sciences, Inc.
(GILD) is the lower-risk stock at 0. 66β versus NanoViricides, Inc. 's 1. 34β — meaning NNVC is approximately 104% more volatile than GILD relative to the S&P 500.
04Which is growing faster — NNVC or GILD?
On earnings-per-share growth, the picture is similar: Gilead Sciences, Inc.
grew EPS 1684% year-over-year, compared to 10. 0% for NanoViricides, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — NNVC or GILD?
Gilead Sciences, Inc.
(GILD) is the more profitable company, earning 28. 9% net margin versus 0. 0% for NanoViricides, Inc. — meaning it keeps 28. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GILD leads at 40. 1% versus 0. 0% for NNVC. At the gross margin level — before operating expenses — GILD leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — NNVC or GILD?
In this comparison, GILD (2.
4% yield) pays a dividend. NNVC does not pay a meaningful dividend and should not be held primarily for income.
07Is NNVC or GILD better for a retirement portfolio?
For long-horizon retirement investors, Gilead Sciences, Inc.
(GILD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66), 2. 4% yield). Both have compounded well over 10 years (GILD: +87. 8%, NNVC: -95. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between NNVC and GILD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
GILD pays a dividend while NNVC does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.